Key facts
- This page summarizes CASCADE INVESTMENT, L.L.C.'s Form 3 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 Sep 2021, 16:24.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
Includes 15,949,483 earn-out shares that will vest in four substantially equal installments if the issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00.
SEC remarks
Exhibit List: Exhibit 24.1 - Power of Attorney (Cascade Investment, L.L.C.); Exhibit 24.2 - Power of Attorney (William H. Gates III)